Simultaneous targeting of insulin-like growth factor-1 receptor and anaplastic lymphoma kinase in embryonal and alveolar rhabdomyosarcoma: A rational choice

European Journal of Cancer

Volumn 49, Issue 16, 2013, Pages 3462-3470

  Van Gaal, J Carlijn ^a   Roeffen, Melissa H S ^a   Flucke, Uta E ^a   Van Der Laak, Jeroen A W M ^a   Van Der Heijden, Gwen ^a   De Bont, Eveline S J M ^b   Suurmeijer, Albert J H ^c   Versleijen Jonkers, Yvonne M H ^a   Van Der Graaf, Winette T A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Alveolar rhabdomyosarcoma; Anaplastic lymphoma kinase receptor; Embryonal rhabdomyosarcoma; In vitro; Insulin like growth factor 1 receptor; Targeted treatment

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; NVP TAE 684; PROTEIN KINASE B; R 1507; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CELL VIABILITY; CHILD; CONCENTRATION RESPONSE; CYTOPLASM; DISEASE SPECIFIC SURVIVAL; DRUG POTENTIATION; EMBRYO; EMBRYONAL RHABDOMYOSARCOMA; FOLLOW UP; HUMAN; HUMAN TISSUE; IC 50; IN VITRO STUDY; INFANT; MAJOR CLINICAL STUDY; NEWBORN; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHABDOMYOSARCOMA; SCHOOL CHILD;

ALVEOLAR RHABDOMYOSARCOMA; ANAPLASTIC LYMPHOMA KINASE RECEPTOR; EMBRYONAL RHABDOMYOSARCOMA; IN VITRO; INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR; TARGETED TREATMENT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL SURVIVAL; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HUMANS; INFANT; INFANT, NEWBORN; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NETHERLANDS; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, IGF TYPE 1; RHABDOMYOSARCOMA, ALVEOLAR; RHABDOMYOSARCOMA, EMBRYONAL; YOUNG ADULT;

EID: 84885182752     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.06.022     Document Type: Article

References (42)

1. J.G. Gurney, J.L. Young, and S.D. Roffers Soft tissue sarcomas L.A.G. Reis, M.A. Smith, J.G. Gurney, Cancer incidence and survival among children and adolescents: United States SEER program, 1975-1995 1999 National Cancer Institute SEER Program [NIH Pub. No. 99-4649] Bethesda, MD p. 111-23
2. H.M. Maurer, M. Beltangady, and E.A. Gehan The intergroup rhabdomyosarcoma study-I. A final report Cancer 61 2 1988 209 220
3. W.M. Crist, J.R. Anderson, and J.L. Meza Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease J Clin Oncol 19 12 2001 3091 3102
4. H.P. McDowell, A.B. Foot, and C. Ellershaw Outcomes in paediatric metastatic rhabdomyosarcoma: results of The International Society of Paediatric Oncology (SIOP) study MMT-98 Eur J Cancer 46 9 2010 1588 1595
5. M. Carli, R. Colombatti, and O. Oberlin European intergroup studies (MMT4-89 and MMT4-91) on childhood metastatic rhabdomyosarcoma: final results and analysis of prognostic factors J Clin Oncol 22 23 2004 4787 4794
6. S. Mazzoleni, G. Bisogno, and A. Garaventa Outcomes and prognostic factors after recurrence in children and adolescents with nonmetastatic rhabdomyosarcoma Cancer 104 1 2005 183 190
7. I. Sultan, I. Qaddoumi, S. Yaser, C. Rodriguez-Galindo, and A. Ferrari Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2,600 patients J Clin Oncol 27 20 2009 3391 3397
8. J. Martín Liberal, L. Lagares-Tena, and M. Sáinz-Jaspeado Targeted therapies in sarcomas: challenging the challenge Sarcoma 2012 2012 Article ID 626094
9. B. Rikhof, J.S. de, A.J. Suurmeijer, C. Meijer, and W.T. van der Graaf The insulin-like growth factor system and sarcomas J Pathol 217 4 2009 469 482
10. A.S. Martins, D. Olmos, E. Missiaglia, and J. Shipley Targeting the insulin-like growth factor pathway in rhabdomyosarcomas: rationale and future perspectives Sarcoma 2011 2011 Article ID 209736
11. O.M. El-Badry, C. Minniti, and E.C. Kohn Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors Cell Growth Differ 1 7 1990 325 331
12. C.P. Minniti, M. Tsokos, W.A. Newton Jr., and L.J. Helman Specific expression of insulin-like growth factor-II in rhabdomyosarcoma tumor cells Am J Clin Pathol 101 2 1994 198 203
13. X. Wan, and L.J. Helman Levels of PTEN protein modulate Akt phosphorylation on serine 473, but not on threonine 308, in IGF-II- overexpressing rhabdomyosarcomas cells Oncogene 22 50 2003 8205 8211
14. M.C. Blandford, F.G. Barr, and J.C. Lynch Rhabdomyosarcomas utilize developmental, myogenic growth factors for disease advantage: a report from the Children's Oncology Group Pediatr Blood Cancer 46 3 2006 329 338
15. D.N. Shapiro, B.G. Jones, L.H. Shapiro, P. Dias, and P.J. Houghton Antisense-mediated reduction in insulin-like growth factor-I receptor expression suppresses the malignant phenotype of a human alveolar rhabdomyosarcoma J Clin Invest 94 3 1994 1235 1242
16. E.A. Kolb, R. Gorlick, and P.J. Houghton Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program Pediatr Blood Cancer 50 6 2008 1190 1197
17. E.A. Kolb, D. Kamara, and W. Zhang R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts Pediatr Blood Cancer 55 1 2010 67 75
18. E.A. Kolb, R. Gorlick, and R. Lock Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program Pediatr Blood Cancer 56 4 2011 595 603
19. A.S. Pappo, S.R. Patel, and J. Crowley R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study J Clin Oncol 29 34 2011 4541 4547
20. P. Schoffski, D. Adkins, and J.Y. Blay Phase II trial of anti-IGF-IR antibody cixutumumab in patients with advanced or metastatic soft-tissue sarcoma and Ewing family of tumors J Clin Oncol 29 2011 [abstr. 10004]
21. D. Olmos, S. Postel-Vinay, and L.R. Molife Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study Lancet Oncol 11 2 2010 129 135
22. F. Huang, W. Hurlburt, and A. Greer Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model Cancer Res 70 18 2010 7221 7231
23. J. Abraham, S.I. Prajapati, and K. Nishijo Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma Mol Cancer Ther 10 4 2011 697 707
24. C. Garofalo, C. Mancarella, and A. Grilli Identification of common and distinctive mechanisms of resistance to different anti-IGF-IR agents in Ewing's Sarcoma Mol Endocrinol 26 9 2012 1603 1616
25. F. Huang, A. Greer, and W. Hurlburt The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors Cancer Res 69 1 2009 161 170
26. D. Olmos, B. Basu, and J.S. de Bono Targeting insulin-like growth factor signaling: rational combination strategies Mol Cancer Ther 9 9 2010 2447 2449
27. J.C. van Gaal, U.E. Flucke, and M.H. Roeffen Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications J Clin Oncol 30 3 2012 308 315
28. D.A. Corao, J.A. Biegel, and C.M. Coffin ALK expression in rhabdomyosarcomas: correlation with histologic subtype and fusion status Pediatr Dev Pathol 12 4 2009 275 283
29. R. Chiarle, C. Voena, C. Ambrogio, R. Piva, and G. Inghirami The anaplastic lymphoma kinase in the pathogenesis of cancer Nat Rev Cancer 8 1 2008 11 23
30. C.D.M. Fletcher, K.K. Unni, and F. Mertens Pathology and genetics of tumours of soft tissue and bone. World Health Organisation classification of tumours 2002 IARC Press Lyon, France p. 146-52
31. A.C. van de Luijtgaarden, Y.M. Versleijen-Jonkers, and M.H. Roeffen Prognostic and therapeutic relevance of the IGF pathway in Ewing's sarcoma patients Target Oncol 2013 [epub ahead of print]
32. L. Zhao, M.G. Wientjes, and J.L. Au Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses Clin Cancer Res 10 23 2004 7994 8004
33. P.J. Houghton, C.L. Morton, and R. Gorlick Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the pediatric preclinical testing program Pediatr Blood Cancer 54 7 2010 921 926
34. B. Basu, D. Olmos, and J.S. de Bono Targeting IGF-1R: throwing out the baby with the bathwater? Br J Cancer 104 1 2011 1 3
35. T. Aleksic, M.M. Chitnis, and O.V. Perestenko Type 1 insulin-like growth factor receptor translocates to the nucleus of human tumor cells Cancer Res 70 16 2010 6412 6419
36. I. Asmane, E. Watkin, and L. Alberti Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas Eur J Cancer 48 16 2012 3027 3035
37. B. Sehat, A. Tofigh, and Y. Lin SUMOylation mediates the nuclear translocation and signaling of the IGF-1 receptor Sci Signal 3 108 2010 ra10
38. S.Y. Lin, K. Makino, and W. Xia Nuclear localization of EGF receptor and its potential new role as a transcription factor Nat Cell Biol 3 9 2001 802 808
39. S.P. Sardi, J. Murtie, S. Koirala, B.A. Patten, and G. Corfas Presenilin-dependent ErbB4 nuclear signaling regulates the timing of astrogenesis in the developing brain Cell 127 1 2006 185 197
40. K. Scotlandi, M.C. Manara, and G. Nicoletti Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors Cancer Res 65 9 2005 3868 3876
41. R.T. Kurmasheva, L. Dudkin, and C. Billups The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma Cancer Res 69 2009 7662 7671
42. H.K. Bid, J. Zhan, D.A. Phelps, R.T. Kurmasheva, and P.J. Houghton Potent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody SCH717454 is reversed by IGF-2 Mol Cancer Ther 11 2012 649 659